Potentiation of therapeutic effects of fatty acids
0 Assignments
0 Petitions
Accused Products
Abstract
The oral administration of an essential fatty acid, preferably eicosapentaenoic acid, at a defined purity together with an inhibitor of COX-1 or COX-2 or LOX or one or more of the FACL enzymes gives improved therapeutic results over administration of the fatty acid alone.
-
Citations
25 Claims
-
1-18. -18. (canceled)
-
19. A method of treating any form of neurological or neurodegenerative disease in a subject, including Parkinsons disease, Alzheimers disease, Huntingtons disease, amyotrophic lateral sclerosis or any other Atriplet repeat disease, stroke, multi-infarct or any other form of dementia, multiple sclerosis, chronic fatigue and epilepsy, comprising orally administering to the subject:
-
a fatty acid preparation consisting essentially of more than 95% pure eicosapentaenoic acid or eicosapentaenoic acid derivative and less than 1% docosahexaenoic acid or a docosahexaenoic acid derivative and less than 1% linoleic acid or a linoleic acid derivative;
in conjunction with an enzyme inhibitor selected from the group consisting of an inhibitor of COX-1 and/or COX-2, an inhibitor of LOX and an inhibitor of one or more of the FACL enzymes. - View Dependent Claims (22, 23, 24, 25)
-
-
20. A method of treating psychiatric disease in a subject, including schizophrenia, schizoaffective disorders, schizotypy, depression, anxiety, bipolar disorder, mania, borderline personality disorder, alcoholism and attention deficit hyperactivity disorder or any other psychiatric illness, comprising orally administering to the subject:
-
a fatty acid preparation consisting essentially of more than 95% pure eicosapentaenoic acid or eicosapentaenoic acid derivative and less than 1% docosahexaenoic acid or a docosahexaenoic acid derivative and less than 1% linoleic acid or a linoleic acid derivative;
in conjunction with an enzyme inhibitor selected from the group consisting of an inhibitor of COX-1 and/or COX-2, an inhibitor of LOX and an inhibitor of one or more of the FACL enzymes.
-
-
21. A method of treating cancer or cancer cachexia in a subject, comprising orally administering to the subject:
-
a fatty acid preparation consisting essentially of more than 95% pure eicosapentaenoic acid or eicosapentaenoic acid derivative and less than 1% docosahexaenoic acid or a docosahexaenoic acid derivative and less than 1% linoleic acid or a linoleic acid derivative;
in conjunction with an enzyme inhibitor selected from the group consisting of an inhibitor of COX-1 and/or COX-2, an inhibitor of LOX and an inhibitor of one or more of the FACL enzymes.
-
Specification